Type 2 Diabetes: Patients Reporting Better Quality of Communication by their Physician Show Improved Self-care

          - 'Encouraging' and 'collaborative' physician communication is linked to better patient outcomes

          - New IntroDia(TM) Survey patient data are presented at American Diabetes Association's(R)  (ADA) 75th Scientific Sessions

          - IntroDia(TM) is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation

          New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed ('add-on'), is linked to future patient self-care and well-being.1 Data from the IntroDia(TM) Survey have quantitatively demonstrated this link in the largest international survey of its kind, using responses from 4,235 people with T2D across 26 countries.*1

          The perceived quality of the 'add-on' conversation by patients was linked to all self-management outcomes surveyed.1 Patients who recalled better quality of communication when interacting with their physicians reported improved self-care and emotional well-being, including improved diabetes-related emotional distress, frequency of exercise and diet, as well as better medication adherence.1

          Dr Matthew Capehorn, UK, GP and member of the IntroDia(TM) Advisory Panel commented, "If not framed properly, the introduction of additional oral medication for type 2 diabetes management can be a challenging moment for patients. An encouraging conversation with a physician can make a real difference to subsequent self-management. We now have data that confirm how important the quality of communication is during this 'add-on' conversation."

          Analysis of the conversations indicated patients distinguish three types of physician statements that contribute to communication quality: 'encouraging', 'collaborative' and 'discouraging'.1 When physicians used 'encouraging' and 'collaborative' statements, patients' perception of the communication quality significantly improved.1 Using 'discouraging' statements had the opposite effect.1

          'Encouraging' communication included statements such as:

          - "My doctor explained that the new medication would help to control my diabetes." 
          - "My doctor told me that the new medication would improve my quality of life."

          'Collaborative' communication examples were:

          - "My doctor invited me to ask questions about my new medication."
          - "My doctor helped to adjust my treatment plan so I could do it in my daily life."

          'Discouraging' communication included statements like:

          - "My doctor told me that my diabetes is out of control."
          - "My doctor told me that I needed more medication because I had failed to take good enough care of myself."

          The analysis also looked into which statements were most frequently recalled by patients from their 'add-on' conversations. 'Encouraging' statements were recalled by up to 85 percent of patients. 'Discouraging' statements were recalled by up to 53 percent of patients.1

          "The patient data demonstrate that physicians are already doing a good job, by most often using 'encouraging' and 'collaborative' statements and using 'discouraging' statements less frequently. However, 'add-on' conversations can still be further improved to help patients make the positive behavioural changes required to manage type 2 diabetes," concluded Dr Capehorn.

          *4,235 people with T2D, out of the total 10,319 included in the IntroDia(TM) Survey, met the necessary criteria to be asked about 'add-on' moment conversations. All 10,319 survey participants were asked about their early 'diagnosis' conversations.

          CONTACT
          Sungjin Kim
          Head of Communications
          Regional Operating Unit South East Asia and South Korea
          Boehringer Ingelheim Singapore Pte.Ltd. 
          Office: +65-6419-7625
          Email: [email protected]

          Reference

          1. Capehorn M, et al. Physician-patient Communication at Prescription of an Additional Oral Agent for Type 2 Diabetes (T2D): Link Between Key Conversation Elements, Physician Empathy and Patient Outcomes -- Insights From the Global IntroDia(TM) Study. Poster 63-LB at the 75th Scientific Sessions of the American Diabetes Association(R) (ADA) 2015, Boston, USA.

 


ข่าวBoehringer Ingelheim+Type 2 Diabetesวันนี้

Type 2 Diabetes: Patients Reporting Better Quality of Communication by their Physician Show Improved Self-care

- 'Encouraging' and 'collaborative' physician communication is linked to better patient outcomes - New IntroDia(TM) Survey patient data are presented at American Diabetes Association's(R) (ADA) 75th Scientific Sessions - IntroDia(TM) is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (

New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results

- Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for...

บริษัทชีวเภสัชภัณฑ์ชั้นนำทั่วเอเชียแปซิฟิก วางใจใช้วีวา ซีอาร์เอ็ม ขับเคลื่อนการติดต่อสื่อสารทางดิจิทัล

บริษัทชีวเภสัชภัณฑ์ระดับท็อป 20 ถึง 18 ราย วางใจให้วีวาเข้ามาวางมาตรฐานส่งเสริมความสัมพันธ์กับลูกค้า วีวา ซิสเต็มส์ (Veeva Systems) (NYSE: VEEV) ประกาศว่า บริษัทชีวเภสัชภัณฑ์ระดับท็อป 20 ถึง 18 ราย...

Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM

Eighteen of the top 20 biopharmas standardize with Veeva to build meaningful customer relationships Veeva Systems (NYSE: VEEV) today announced that 18 of the top 20 biopharmas in Asia Pacific are using Veeva CRM for more...

Boehringer Ingelheim Thailand Honored As Top Employer For The Fifth Consecutive Year

Boehringer Ingelheim is one of 15 global Top Employers worldwide Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute(R) Outstanding employer benefits with emphasis...

เบอริงเกอร์ อินเกลไฮม์ ประเทศไทย คว้ารางวัลนายจ้างดีเด่น 5 ปีซ้อน

เบอริงเกอร์ อินเกลไฮม์ ขึ้นแท่นหนึ่งใน 15 สุดยอดนายจ้างระดับโลก ได้รับการยอมรับระดับโลกและการรับรองนายจ้างดีเด่นใน 29 ประเทศจากสถาบันท็อป เอ็มพลอยเยอร์ส สิทธิประโยชน์ที่โดดเด่นจากนายจ้าง โดยเน้นเรื่องความเป็นอยู่ที่ดี สภาพ...

เบอริงเกอร์ อินเกลไฮม์ ได้รับรางวัลนายจ้างดีเด่นประจำปี 2564 ในประเทศไทย ภูมิภาคเอเชียตะวันออกเฉียงใต้ และเกาหลีใต้

นับเป็นปีที่สองที่เบอริงเกอร์ อินเกลไฮม์ ได้รับการยกย่องจากสถาบัน Top Employers Institute สำหรับแนวปฏิบัติด้านทรัพยากรบุคคลที่โดดเด่นของบริษัท ซึ่งครอบคลุมการดำเนินงานในประเทศไทย อิน...

Boehringer Ingelheim named Top Employer in Thailand, across Southeast Asia, and South Korea for 2021

Awarded by Top Employers Institute, this marks the second year that Boehringer Ingelheim was collectively recognized for its outstanding people practices across Indonesia, Malaysia, Philippines,...

Financial year 2018: Boehringer Ingelheim grows and invests

- Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases - Operating growth outpaces the market in all businesses - Technical integration of the animal health business acquired in 2017 successfully...